Matthias P. Ebert

7.1k total citations · 1 hit paper
161 papers, 5.1k citations indexed

About

Matthias P. Ebert is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Matthias P. Ebert has authored 161 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Surgery, 56 papers in Oncology and 54 papers in Molecular Biology. Recurrent topics in Matthias P. Ebert's work include Pancreatic and Hepatic Oncology Research (33 papers), Helicobacter pylori-related gastroenterology studies (22 papers) and Pancreatitis Pathology and Treatment (21 papers). Matthias P. Ebert is often cited by papers focused on Pancreatic and Hepatic Oncology Research (33 papers), Helicobacter pylori-related gastroenterology studies (22 papers) and Pancreatitis Pathology and Treatment (21 papers). Matthias P. Ebert collaborates with scholars based in Germany, United States and China. Matthias P. Ebert's co-authors include Peter Malfertheiner, Christoph Röcken, Murray Korc, Helmut Friess, Jun Yu, Markus W. Büchler, Helmut Frieß, Hans G. Beger, Yoichiro Yamanaka and Leslie I. Gold and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Matthias P. Ebert

155 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines

2024 47 citations Dyke Ferber, Isabella C. Wiest et al. NEJM AI profile →

Peers

Countries citing papers authored by Matthias P. Ebert

Since Specialization

Citations

This map shows the geographic impact of Matthias P. Ebert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias P. Ebert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias P. Ebert more than expected).

Fields of papers citing papers by Matthias P. Ebert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias P. Ebert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias P. Ebert. The network helps show where Matthias P. Ebert may publish in the future.

Co-authorship network of co-authors of Matthias P. Ebert

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias P. Ebert. A scholar is included among the top collaborators of Matthias P. Ebert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias P. Ebert. Matthias P. Ebert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models 2025 ·Cancer Communications ·Monika Raab, Balázs Győrffy, Samuel Peña‐Llopis, Daniela Fietz, (unknown), (unknown), Matthias P. Ebert, (unknown), Sven Becker, Mourad Sanhaji, (unknown)	1
2	Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT 2025 ·Seminars in Immunopathology ·A. Centeno, (unknown), Matthias P. Ebert, A Thomann, Wolfgang Reindl	0
3	Deidentifying Medical Documents with Local, Privacy-Preserving Large Language Models: The LLM-Anonymizer 2025 ·NEJM AI ·Isabella C. Wiest, (unknown), F M Wolf, Dyke Ferber, Marko van Treeck, (unknown), Matthias P. Ebert, C. Benedikt Westphalen, Martin Wermke, Jakob Nikolas Kather	10
4	GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines breakdown → 2024 ·NEJM AI ·Dyke Ferber, Isabella C. Wiest, Georg Wölflein, Matthias P. Ebert, Gernot Beutel, Jan‐Niklas Eckardt, Daniel Truhn, Christoph Springfeld, Dirk Jäger, Jakob Nikolas Kather	47
5	Deep sight: enhancing periprocedural adverse event recording in endoscopy by structuring text documentation with privacy-preserving large language models 2024 ·PubMed ·Isabella C. Wiest, Dyke Ferber, (unknown), Matthias P. Ebert, (unknown), Jakob Nikolas Kather	4
6	Retinoic acid generates a beneficial microenvironment for liver progenitor cell activation in acute liver failure 2024 ·Hepatology Communications ·(unknown), (unknown), Stefan Munker, Wenjing Wang, Rilu Feng, Roman Liebe, Yujia Li, (unknown), Hui Liu, Chen Shao, Matthias P. Ebert, Huiguo Ding, Steven Dooley, (unknown), (unknown)	0
7	Evaluation of four chatbots in autoimmune liver disease: A comparative analysis 2024 ·Annals of Hepatology ·(unknown), (unknown), (unknown), (unknown), Heike Bantel, Marcos Girala, Matthias P. Ebert, Florian van Bömmel, Andreas Geier, Andrés Gómez-Aldana, Kevin Yau, Mário Reis Álvares‐da‐Silva, (unknown), Ezequiel Ridruejo, Arndt Weinmann, Andreas Teufel	6
8	Validation of the German version of the Short Health Scale – a brief, valid and reliable instrument to assess health-related quality of life in German-speaking patients with inflammatory bowel diseases 2023 ·Zeitschrift für Gastroenterologie ·(unknown), Nikolaus Kleindienst, (unknown), Philipp A. Thomann, Matthias P. Ebert, Wolfgang Reindl, A Thomann	1
9	The Interplay of TGF-β1 and Cholesterol Orchestrating Hepatocyte Cell Fate, EMT, and Signals for HSC Activation 2023 ·Cellular and Molecular Gastroenterology and Hepatology ·(unknown), (unknown), Mei Han, (unknown), (unknown), Roman Liebe, Ye Yao, Seddik Hammad, (unknown), (unknown), Claudia Rubie, (unknown), Matthias Glanemann, Matthias P. Ebert, Ralf Weiskirchen, Yoav I. Henis, Marcelo Ehrlich, Steven Dooley	10
10	Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid–case report and review of the literature 2023 ·Clinics and Research in Hepatology and Gastroenterology ·(unknown), Christoph Antoni, Matthias P. Ebert, (unknown), Michael Hirth	4
11	Deep View of HCC Gene Expression Signatures and Their Comparison with Other Cancers 2022 ·Cancers ·(unknown), Timo Itzel, Matthias P. Ebert, Andreas Teufel	2
12	Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B 2022 ·Canadian Journal of Gastroenterology and Hepatology ·(unknown), Liping Zhuang, (unknown), Yee Hui Yeo, Le Tao, (unknown), Wenting Ma, (unknown), Zongguo Yang, Yanqin Yang, Dongying Xue, (unknown), Rilu Feng, Matthias P. Ebert, Steven Dooley, Ekihiro Seki, Ping Liu, Cheng Liu	3
13	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) 2019 ·BMC Cancer ·Nadja M. Meindl‐Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, (unknown), Matthias P. Ebert, (unknown)	21
14	Monitoring and predicting disease activity in autoimmune pancreatitis with the M-ANNHEIM-AiP-Activity-Score 2017 ·Pancreatology ·Michael Hirth, Miroslav Vujasinović, (unknown), Christel Weiß, Matthias Löhr, Matthias P. Ebert, Alexander Schneider	14
15	Risk of Cancer in Patients with Autoimmune Pancreatitis: A Single-Center Experience from Germany 2017 ·Digestion ·Alexander Schneider, Michael Hirth, (unknown), Christel Weiß, Matthias Löhr, Matthias P. Ebert, Roland H. Pfützer	31
16	Prevalence and Incidence of Autoimmune Pancreatitis in the Population Living in the Southwest of Germany 2017 ·Digestion ·Alexander Schneider, Henrik J. Michaely, Christel Weiß, Michael Hirth, Felix Rückert, Torsten J. Wilhelm, Stefan O. Schönberg, Alexander Marx, Manfred V. Singer, Matthias Löhr, Matthias P. Ebert, Roland H. Pfützer	25
17	Expression of G1 Phase Cyclins in Human Gastric Cancer and Gastric Mucosa of First-Degree Relatives 2002 ·Digestive Diseases and Sciences ·Stephan Miehlke, Jun Yu, Matthias P. Ebert, (unknown), Michael Vieth, Eberhard Kuhlisch, (unknown), (unknown), (unknown), Peter Malfertheiner, Gerhard Ehninger, E. Bayerdörffer, Manfred Stolte	13
18	Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non‐neoplastic gastric tissues 2002 ·The Journal of Pathology ·Wai K. Leung, Jun Yu, Francis K.L. Chan, Ka‐Fai To, Michael W.Y. Chan, Matthias P. Ebert, Enders K. Ng, S. C. Sydney Chung, Peter Malfertheiner, Joseph J.�Y. Sung	93
19	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density 2001 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·H. Kasper, Matthias P. Ebert, Peter Malfertheiner, Albert Roessner, C. James Kirkpatrick, (unknown)	54
20	Induction of TFF1 gene expression in pancreas overexpressing transforming growth factor α 1999 ·Gut ·Matthias P. Ebert, Juliane Hoffmann, Carsten Haeckel, (unknown), R Schmid, Martin Wagner, G. Adler, H.-U. Schulz, Albert Roessner, Werner Hoffmann, Peter Malfertheiner	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact